Cargando…

A single point mutation in the Plasmodium falciparum 3′–5′ exonuclease does not alter piperaquine susceptibility

BACKGROUND: The rise in Plasmodium falciparum resistance to dihydroartemisinin–piperaquine (DHA–PPQ) treatment has been documented in the Greater Mekong Subregion with associations with mutations in the P. falciparum chloroquine resistance transporter (pfcrt) and plasmepsin 2 (pfpm2) genes. However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Boonyalai, Nonlawat, Kirativanich, Kirakarn, Thamnurak, Chatchadaporn, Praditpol, Chantida, Vesely, Brian A., Wojnarski, Mariusz, Griesenbeck, John S., Waters, Norman C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034581/
https://www.ncbi.nlm.nih.gov/pubmed/35459163
http://dx.doi.org/10.1186/s12936-022-04148-z
_version_ 1784693139311689728
author Boonyalai, Nonlawat
Kirativanich, Kirakarn
Thamnurak, Chatchadaporn
Praditpol, Chantida
Vesely, Brian A.
Wojnarski, Mariusz
Griesenbeck, John S.
Waters, Norman C.
author_facet Boonyalai, Nonlawat
Kirativanich, Kirakarn
Thamnurak, Chatchadaporn
Praditpol, Chantida
Vesely, Brian A.
Wojnarski, Mariusz
Griesenbeck, John S.
Waters, Norman C.
author_sort Boonyalai, Nonlawat
collection PubMed
description BACKGROUND: The rise in Plasmodium falciparum resistance to dihydroartemisinin–piperaquine (DHA–PPQ) treatment has been documented in the Greater Mekong Subregion with associations with mutations in the P. falciparum chloroquine resistance transporter (pfcrt) and plasmepsin 2 (pfpm2) genes. However, it is unclear whether other genes also play a role with PPQ resistance, such as the E415G mutation in the exonuclease (pfexo) gene. The aim of this study was to investigate the role of this mutation in PPQ resistance by generating transgenic parasites expressing the pfexo-E415G mutant allele. METHODS: Transgenic parasite clones carrying the E415G mutation in PfEXO of the B5 isolate were derived by CRISPR-Cas9 gene editing and verified using PCR and gene sequencing. Polymorphisms of pfkelch-13, pfcrt, and pfexo were examined by PCR while the copy number variations of pfpm2 were examined by both relative quantitative real-time PCR and the duplication breakpoint assay. Drug sensitivity against a panel of antimalarials, the ring-stage survival assay (RSA), the PPQ survival assay (PSA), and bimodal dose-response curves were used to evaluate antimalarial susceptibility. RESULTS: The transgenic line, B5-rexo-E415G-B8, was successfully generated. The PPQ-IC(90), %PPQ survival, and the bimodal dose-response clearly showed that E415G mutation in PfEXO of B5 isolate remained fully susceptible to PPQ. Furthermore, growth assays demonstrated that the engineered parasites grew slightly faster than the unmodified parental isolates whereas P. falciparum isolates harbouring pfkelch-13, pfcrt, and pfexo mutations with multiple copies of pfpm2 grew much more slowly. CONCLUSIONS: Insertion of the E415G mutation in PfEXO did not lead to increased PPQ-IC(90) and %PPQ survival, suggesting that this mutation alone may not be associated with PPQ resistance, but could still be an important marker if used in conjunction with other markers for monitoring PPQ-resistant parasites. The results also highlight the importance of monitoring and evaluating suspected genetic mutations with regard to parasite fitness and resistance. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12936-022-04148-z.
format Online
Article
Text
id pubmed-9034581
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-90345812022-04-24 A single point mutation in the Plasmodium falciparum 3′–5′ exonuclease does not alter piperaquine susceptibility Boonyalai, Nonlawat Kirativanich, Kirakarn Thamnurak, Chatchadaporn Praditpol, Chantida Vesely, Brian A. Wojnarski, Mariusz Griesenbeck, John S. Waters, Norman C. Malar J Research BACKGROUND: The rise in Plasmodium falciparum resistance to dihydroartemisinin–piperaquine (DHA–PPQ) treatment has been documented in the Greater Mekong Subregion with associations with mutations in the P. falciparum chloroquine resistance transporter (pfcrt) and plasmepsin 2 (pfpm2) genes. However, it is unclear whether other genes also play a role with PPQ resistance, such as the E415G mutation in the exonuclease (pfexo) gene. The aim of this study was to investigate the role of this mutation in PPQ resistance by generating transgenic parasites expressing the pfexo-E415G mutant allele. METHODS: Transgenic parasite clones carrying the E415G mutation in PfEXO of the B5 isolate were derived by CRISPR-Cas9 gene editing and verified using PCR and gene sequencing. Polymorphisms of pfkelch-13, pfcrt, and pfexo were examined by PCR while the copy number variations of pfpm2 were examined by both relative quantitative real-time PCR and the duplication breakpoint assay. Drug sensitivity against a panel of antimalarials, the ring-stage survival assay (RSA), the PPQ survival assay (PSA), and bimodal dose-response curves were used to evaluate antimalarial susceptibility. RESULTS: The transgenic line, B5-rexo-E415G-B8, was successfully generated. The PPQ-IC(90), %PPQ survival, and the bimodal dose-response clearly showed that E415G mutation in PfEXO of B5 isolate remained fully susceptible to PPQ. Furthermore, growth assays demonstrated that the engineered parasites grew slightly faster than the unmodified parental isolates whereas P. falciparum isolates harbouring pfkelch-13, pfcrt, and pfexo mutations with multiple copies of pfpm2 grew much more slowly. CONCLUSIONS: Insertion of the E415G mutation in PfEXO did not lead to increased PPQ-IC(90) and %PPQ survival, suggesting that this mutation alone may not be associated with PPQ resistance, but could still be an important marker if used in conjunction with other markers for monitoring PPQ-resistant parasites. The results also highlight the importance of monitoring and evaluating suspected genetic mutations with regard to parasite fitness and resistance. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12936-022-04148-z. BioMed Central 2022-04-22 /pmc/articles/PMC9034581/ /pubmed/35459163 http://dx.doi.org/10.1186/s12936-022-04148-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Boonyalai, Nonlawat
Kirativanich, Kirakarn
Thamnurak, Chatchadaporn
Praditpol, Chantida
Vesely, Brian A.
Wojnarski, Mariusz
Griesenbeck, John S.
Waters, Norman C.
A single point mutation in the Plasmodium falciparum 3′–5′ exonuclease does not alter piperaquine susceptibility
title A single point mutation in the Plasmodium falciparum 3′–5′ exonuclease does not alter piperaquine susceptibility
title_full A single point mutation in the Plasmodium falciparum 3′–5′ exonuclease does not alter piperaquine susceptibility
title_fullStr A single point mutation in the Plasmodium falciparum 3′–5′ exonuclease does not alter piperaquine susceptibility
title_full_unstemmed A single point mutation in the Plasmodium falciparum 3′–5′ exonuclease does not alter piperaquine susceptibility
title_short A single point mutation in the Plasmodium falciparum 3′–5′ exonuclease does not alter piperaquine susceptibility
title_sort single point mutation in the plasmodium falciparum 3′–5′ exonuclease does not alter piperaquine susceptibility
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034581/
https://www.ncbi.nlm.nih.gov/pubmed/35459163
http://dx.doi.org/10.1186/s12936-022-04148-z
work_keys_str_mv AT boonyalainonlawat asinglepointmutationintheplasmodiumfalciparum35exonucleasedoesnotalterpiperaquinesusceptibility
AT kirativanichkirakarn asinglepointmutationintheplasmodiumfalciparum35exonucleasedoesnotalterpiperaquinesusceptibility
AT thamnurakchatchadaporn asinglepointmutationintheplasmodiumfalciparum35exonucleasedoesnotalterpiperaquinesusceptibility
AT praditpolchantida asinglepointmutationintheplasmodiumfalciparum35exonucleasedoesnotalterpiperaquinesusceptibility
AT veselybriana asinglepointmutationintheplasmodiumfalciparum35exonucleasedoesnotalterpiperaquinesusceptibility
AT wojnarskimariusz asinglepointmutationintheplasmodiumfalciparum35exonucleasedoesnotalterpiperaquinesusceptibility
AT griesenbeckjohns asinglepointmutationintheplasmodiumfalciparum35exonucleasedoesnotalterpiperaquinesusceptibility
AT watersnormanc asinglepointmutationintheplasmodiumfalciparum35exonucleasedoesnotalterpiperaquinesusceptibility
AT boonyalainonlawat singlepointmutationintheplasmodiumfalciparum35exonucleasedoesnotalterpiperaquinesusceptibility
AT kirativanichkirakarn singlepointmutationintheplasmodiumfalciparum35exonucleasedoesnotalterpiperaquinesusceptibility
AT thamnurakchatchadaporn singlepointmutationintheplasmodiumfalciparum35exonucleasedoesnotalterpiperaquinesusceptibility
AT praditpolchantida singlepointmutationintheplasmodiumfalciparum35exonucleasedoesnotalterpiperaquinesusceptibility
AT veselybriana singlepointmutationintheplasmodiumfalciparum35exonucleasedoesnotalterpiperaquinesusceptibility
AT wojnarskimariusz singlepointmutationintheplasmodiumfalciparum35exonucleasedoesnotalterpiperaquinesusceptibility
AT griesenbeckjohns singlepointmutationintheplasmodiumfalciparum35exonucleasedoesnotalterpiperaquinesusceptibility
AT watersnormanc singlepointmutationintheplasmodiumfalciparum35exonucleasedoesnotalterpiperaquinesusceptibility